Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Blefarix is an ophthalmic hygiene product developed and marketed by DÁVI, a Portuguese pharmaceutical laboratory specializing in ophthalmology. The product is primarily available as sterile, single-use wipes, though it is also offered in gel and solution formats. It is specifically formulated for the hygiene of eyelids and eyelashes, aimed at removing excess flaking and seborrhea. The formulation contains botanical extracts such as *Rosa centifolia* flower water and *Centaurea cyanus* flower water, along with bisabolol, which provide soothing and cleansing properties. Blefarix is indicated for the management of eyelid hygiene in conditions including blepharitis, conjunctivitis, and lacrimal duct obstruction, and is suitable for use across all age groups, including infants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Blefarix.